Cargando…
Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities
Since their introduction into clinical use in the 1970s, aromatase inhibitors have been a cornerstone of therapy for estrogen-receptor positive breast cancer in postmenopausal women. Unfortunately, this therapy leads to estrogen depletion in the body, which can lead to unpleasant side effects such a...
Autores principales: | Grigorian, Nelly, Baumrucker, Steven J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935546/ https://www.ncbi.nlm.nih.gov/pubmed/35321462 http://dx.doi.org/10.1177/20503121221078722 |
Ejemplares similares
-
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010) -
Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms
por: Henry, N Lynn, et al.
Publicado: (2021) -
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013) -
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021) -
Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)